Breaking News, Collaborations & Alliances

BostonGene and Daiichi Sankyo to Bring AI Intel to ADC Development Program

The collaboration is intended to deliver decision-ready insights directly informing patient selection strategies.

Author Image

By: Patrick Lavery

Content Marketing Editor

BostonGene and Daiichi Sankyo are collaborating to integrate artificial intelligence (AI)-driven translational intelligence into an antibody-drug conjugate (ADC) development program. The aim of the ADC program, developed by Daiichi Sankyo, is to move beyond standard exploratory biomarker analysis. To do this, the program promises to deliver decision-ready insights to directly inform patient selection strategies. It will also assist in development prioritization and translational positionin...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters